Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07442058 · ClinicalTrials.gov registry record · NA
Accelerated and Extended-iTBS Targeting Inhibitory Control in Veterans With ADHD
A NA study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT07442058: Clinical Trial NA study, sponsored by VA Office of Research and Development.
NCT07442058 is a NA study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07442058, a NA study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
Impaired inhibitory response manifests clinically as increased impulsivity, which leads to poorer affective, cognitive, social, and occupational functioning. Neuropsychiatric disorders prevalent among Veterans, such as Attention Deficit/Hyperactivity Disorder (ADHD), are associated with poor inhibitory control. The mainstay of clinical treatment for ADHD is psychostimulants, yet these medications have significant risks, including dependence and numerous side effects. Thus, novel and non-pharmacological therapeutic strategies are needed. Intermittent Theta Burst Stimulation, a newer form of transcranial magnetic stimulation, has emerged as a promising tool for modulating inhibitory neuronal circuits. This research proposal will investigate the feasibility and acceptability of iTBS on inhibitory control and impulsivity through a randomized controlled trial to inform clinical observations. The long-term goal is to improve impulsivity, social and occupational functioning, and enhance the quality of life for Veterans.
Primary Outcome
Feasibility will be determined through follow-up completion. This will be calculated as simple proportion based on attended and scheduled follow-up sessions.
Interventions
- DEVICE Sham Stimulation
- DEVICE Intermittent Theta-Burst Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-07-01 |
| Phase | NA |
What is known before NCT07442058 opens enrollment
NCT07442058 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Stimulation is the first listed.
NCT07442058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07442058 about?
NCT07442058 is a clinical study titled "Accelerated and Extended-iTBS Targeting Inhibitory Control in Veterans With ADHD". Impaired inhibitory response manifests clinically as increased impulsivity, which leads to poorer affective, cognitive, social, and occupational functioning. Neuropsychiatric disorders prevalent among Veterans, such as Attention Deficit/Hyperactivity Disorder (ADHD), are associated with poor inhibit...
What is the current status of trial NCT07442058?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2026-07-01. Estimated completion is 2028-07-01.
What interventions are being tested in trial NCT07442058?
The interventions under investigation include: Sham Stimulation (DEVICE), Intermittent Theta-Burst Stimulation (DEVICE).
Who is sponsoring clinical trial NCT07442058?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07442058's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI